Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Zhang S, Li M, Liu M, Patten ND, Labaf M, Jeong J, Sun H, Lourie J, Zou K, Patalano S, Mulhearn MJ, Macoska JA, Gao S, Andreotti R, Pennuto M, Han D, Balk SP, Cai C. Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer. Proc Natl Acad Sci U S A. 2026 Sep 15; 123(37):e2534152123.
-
Griffin JN, Danowski ME, Gerety HL, Lafferty K, Clayman ML, Antwi AA, Bertero MG, Brunette CA, Gillespie C, Guentert L, Lennon NJ, Martin J, Patel LS, Vassy JL. Development and pilot testing of a prostate cancer polygenic risk report. BMC Med Genomics. 2026 Jul 30; 19(1).
-
Chernysheva D, Di Bello F, Avesani G, Baboudjian M, Barret E, Breda A, Briganti A, Budäus L, Comperat E, Diamand R, De Meerleer G, De Rooij M, Giganti F, Giannarini G, Goffin K, Hernández Mancera J, Jereczek-Fossa BA, Kasivisvanathan V, Kesch C, Klotz L, Lughezzani G, Malavaud B, Moore C, Murphy D, Oprea-Lager D, Padhani A, Panebianco V, Ploussard G, Rannikko A, Raspollini MR, Rembak-Szynkiewicz J, Schoots I, Spohn SK, Stabile A, Tilki D, Tree A, Walz J, MacLennan S, Sanguedolce F. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol. 2026 Sep; 90(3):212-224.
-
Buller DM, Dubovic V, Martin WE, Rosenfeld B, Sherman A, Faust WC, Ginzburg S, Wagner JR, Correa AF, Pinto K, Albertsen PC, Kutikov A, Ristau BT. Multi-Institutional Assessment of Performance Metrics for MRI-Targeted Transperineal Prostate Biopsy. J Urol. 2026 Oct; 216(4):511-517.
-
Xiang JC, Xia ZY, Sun JX, Ye GC, Wang Y, Yang J, Wang SG, Xia QD. First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer. J Immunother Cancer. 2026 May 13; 14(5).
-
Xia QD, Xu MY, Zhu XH, Yang J, Wang SG. PSMA PET/MRI-US Fusion-Guided Irreversible Electroporation for Focal Therapy of Prostate Cancer. Clin Nucl Med. 2026 Aug 01; 51(8):661-663.
-
Abbas G, Bokhari TH, Iqbal MA, Rehman S, Ali A. Mechanosynthesis and computational studies of new imidazole-based selenium adducts as potential anticancer agents against human prostate and cervical cancer. Future Med Chem. 2026 05; 18(9):1059-1069.
-
Zhou L, DeMarco KD, Murphy KC, Wu Z, Li J, Johnson C, Liu B, Giwa HK, Ma B, Bhalerao N, Li J, Jiang Z, Bai S, Parikh CN, Ye T, Simin K, Zhu LJ, Pitarresi JR, Wu H, Ruscetti M. p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. Cancer Discov. 2026 Mar 02; 16(3):571-591.
-
Ortner G, Hoderlein X, Barbato F, Beyersdorff D, Budäus L, Burger IA, Eiber M, Graefen M, Hadaschik B, Haese A, Herrmann K, Maack L, Maric I, Mattei A, Rauscher I, Salomon G, Sauer M, Schimmöller L, Schlaefer A, Schlemmer HP, Spohn SKB, Umutlu L, Walz J, Würnschimmel C, Koehler D, Maurer T. The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer. J Nucl Med. 2026 01 02; 67(1):154-159.
-
Fonteyne V, Tree A, Castro E, Touijer K, Walz J. Prostate cancer. Lancet. 2026 02 07; 407(10528):622-636.